Search Results for: covid-19
Articles
Vaccitech Reports Promising Interim Efficacy Analysis in Phase 1b/2a Clinical Study in Chronic HBV December 7, 2021
Vaccitech plc recently announced a promising interim analysis of safety and efficacy data from the HBV002 study, including a review...Enlivex Receives Notice of Allowance for US Patent Application Covering the Treatment of Sepsis Patients With Allocetra December 6, 2021
Enlivex Therapeutics Ltd. recently announced the US Patent and Trademark Office issued a notice of allowance for a new patent...SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected With Influenza Virus December 1, 2021
SAB Biotherapeutics recently announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and….
Vaxart Announces Acquisition of Second GMP Manufacturing Facility December 1, 2021
Vaxart, Inc. has entered into an agreement with Kindred Bioscience, Inc. for the purchase of KindredBio’s manufacturing equipment and sublease...APTAMER TECHNOLOGY - From Postal Codes to GPS: Building Better Drug Conjugates With Aptamers November 30, 2021
David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.
Heat Biologics Unveils a Novel Cellular Vaccine Platform Targeting Known & Unknown Emerging Biological Threats November 30, 2021
Heat Biologics, Inc. recently unveiled its new RapidVax cellular vaccine platform at the 2021 World Antiviral Congress. RapidVax is designed...Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation November 23, 2021
Revive Therapeutics Ltd. recently announced it has filed an application with the US FDA to receive Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver….
Vaccitech’s VTP-300 Was Well-Tolerated & Induced T cells Against All Targeted HBV Antigens in Both Healthy Volunteers & Patients With Chronic HBV Infection in Interim Analyses November 12, 2021
Vaccitech plc recently announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in...Baxter Announced $100-Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility November 11, 2021
Baxter International Inc. recently announced an approximately $100-million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is….
Synlogic & Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria November 9, 2021
Synlogic, Inc. and Ginkgo Bioworks recently announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for the treatment of...Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity Against Human Common Coronaviruses, Noroviruses, Rhinoviruses & Enteroviruses November 8, 2021
Cocrystal Pharma, Inc. recently announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common...TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients November 8, 2021
TFF Pharmaceuticals, Inc. recently announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF...PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial November 5, 2021
PDC*line Pharma recently announced the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 Phase 1/2 clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer….
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of its mRNA Cytomegalovirus (CMV) Vaccine October 27, 2021
Moderna, Inc. recently announced the first participant has been dosed in the Phase 3 pivotal registration study of mRNA-1647, the Company’s...Halberd Files Provisional Patent on Breakthrough Obesity Treatment October 26, 2021
Halberd Corporation recently announced the filing of a provisional patent application with the US Patent and Trademark Office covering their...Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial October 22, 2021
Phathom Pharmaceuticals, Inc. recently announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal Phase 3 trial evaluating….
CEL-SCI’s Multikine Immunotherapy Produces Significant Survival Benefit in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head & Neck Cancer Phase 3 Study October 15, 2021
CEL-SCI Corporation recently announced results from its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine (Leukocyte Interleukin, Injection)*...Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer October 13, 2021
Veru Inc. recently announced it has enrolled the first patient in its Phase 3 ARTEST registration trial of enobosarm, an...Acer Therapeutics & Relief Therapeutics Announce FDA Acceptance for Filing of NDA October 12, 2021
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA recently announced the US FDA has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the….
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management October 12, 2021
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. recently announced a definitive agreement pursuant to which Pacira will acquire Flexion for...
